Efficacy of Ocrelizumab in Autoimmune Encephalitis

NCT03835728 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Failed to meet target enrollment and study was discontinued

Conditions

Autoimmune Encephalitis

Interventions

DRUG: Ocrelizumab
DRUG: Saline

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]